Xvivo Perfusion AB (publ) (XVIVO) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you so much and good morning and good afternoon and welcome to XVivo's earning call for the second quarter of 2025. I go to the first page after the front page. So today's presenters are me, Kristoffer Rosenblatt, CEO of XVivo and Kristoffer Nordström, CFO. And with that, we go to slide two, the Q2 finance at the glance. I am disappointed to report that Q2 shows negative top line growth compared to the same quarter last year. The three main reasons are a slower than expected long market that led to some destocking, lack of hard sales compared to both expectations and last year, and thirdly, a weaker US dollar. The positive news, however, in the quarter two are that where we invest in field force, we see strong growth and a positive momentum. For example, the U.S. lung sales to clinic and opioids grew by 26 percent. Liver in Europe grew by 32 percent and kidney sales in the U.S. grew by 47 percent during the second quarter of this year. The quarter also showed great progress in terms of milestones for future growth. The key event was the ISHLT in April and the reception of the European Heart Study. With one year data now available, we can conclude that the 76% risk reduction in severe PDD led to improved patient survival. This was expected and known by everyone in the heart transplant community, but the clear correlation also in the study strengthened the conviction. I can't remember how many times I got the question during ISHTT, how can I buy this device from surgeons I met during the meeting? We also have seen progress in the heart approval process and the Canadian launch activities for the abdominal portfolio. Last year, we saw that the two largest US transplant clinics grew the program safely by evaluating lungs. During ISHC, the presentation from Cleveland...